论文部分内容阅读
BACKGROUND In recent decades,neoadjuvant therapy(NT)has been the standardized treatment for locally advanced rectal cancer(LARC).Approximately 8%-35%of patients with LARC who received NT were reported to have achieved a complete pathological response(pCR)